NASDAQ · Healthcare · Biotechnology
Scribe Therapeutics Inc.
SCTX
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. CEO Benjamin L. Oakes · Market cap $284.3M.
$17.57
+1.24 · +7.59%
52w hi $39.6052w lo $13.50
Off 52w high 28.0%
87
STRONG
Current InsiderScore
Corp · 90d
7
7 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
6
4 strong · 2 notable
Analyst consensus
—
—
Section 01
Recent Form 4 filings
7 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Jul 28 | Behzad Aghazadeh | Buy | 7,905 | $18.25 | +$144K | 54 | |
| Jul 27 | AH Bio Fund II, L.P. | Buy | 333,333 | $15.00 | +$5.00M | 81 | |
| Jul 27 | ORBIMED ADVISORS LLC | Buy | 1,000,000 | $15.00 | +$15.00M | 87 | |
| Jul 27 | Carl L Gordon | Buy | 1,000,000 | $15.00 | +$15.00M | 87 | |
| Jul 24 | Behzad Aghazadeh | Buy | 50,000 | $22.31 | +$1.12M | 60 | |
| Jul 24 | Behzad Aghazadeh | Buy | 2,333,333 | $15.00 | +$35.00M | 76 | |
| Jul 23 | Svetlana Lucas | Chief Business Officer | Buy | 3,000 | $15.00 | +$45K | 60 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
NovDecJanFebMarAprMayJunJulAugSepOct